These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9632583)

  • 1. Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P. carinii pneumonia.
    Gigliotti F; Wiley JA; Harmsen AG
    Infect Immun; 1998 Jul; 66(7):3179-82. PubMed ID: 9632583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii.
    Tesini BL; Wright TW; Malone JE; Haidaris CG; Harber M; Sant AJ; Nayak JL; Gigliotti F
    Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28031260
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization.
    Smulian AG; Sullivan DW; Theus SA
    Microbes Infect; 2000 Feb; 2(2):127-36. PubMed ID: 10742685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein A is the immunodominant antigen of Pneumocystis carinii in mice following immunization.
    Gigliotti F; McCool T
    Parasitol Res; 1996; 82(1):90-1. PubMed ID: 8825453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of Pneumocystis carinii antigens by local antibody-secreting cells following resolution of P. carinii pneumonia in mice.
    Gigliotti F; Garvy BA; Haidaris CG; Harmsen AG
    J Infect Dis; 1998 Jul; 178(1):235-42. PubMed ID: 9652446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with Pneumocystis carinii A12
    Tong T; Wang Z; Xu Y; Shen J
    BMC Immunol; 2021 Jun; 22(1):40. PubMed ID: 34174820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific T-cell response to a Pneumocystis carinii surface glycoprotein (gp120) after immunization and natural infection.
    Fisher DJ; Gigliotti F; Zauderer M; Harmsen AG
    Infect Immun; 1991 Oct; 59(10):3372-6. PubMed ID: 1894351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization confers protection against murine Pneumocystis carinii lung infection.
    Pascale JM; Shaw MM; Durant PJ; Amador AA; Bartlett MS; Smith JW; Gregory RL; McLaughlin GL
    Infect Immun; 1999 Feb; 67(2):805-9. PubMed ID: 9916094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection.
    Ruan S; Cai Y; Ramsay AJ; Welsh DA; Norris K; Shellito JE
    Vaccine; 2017 Jan; 35(4):672-679. PubMed ID: 28012778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.
    Bartlett MS; Angus WC; Shaw MM; Durant PJ; Lee CH; Pascale JM; Smith JW
    Clin Diagn Lab Immunol; 1998 Jan; 5(1):74-7. PubMed ID: 9455884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active immunization against Pneumocystis carinii with p55-v3 DNA vaccine in rats.
    Feng Y; Guo S; Jiang T; Han X; Liu P; Wu T; Luo Y
    Can J Microbiol; 2011 May; 57(5):375-81. PubMed ID: 21529125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific T-cell response to a Pneumocystis carinii surface glycoprotein (gp120).
    Fisher DJ; Gigliotti F; Zauderer M; Harmsen AG
    J Protozool; 1991; 38(6):22S-23S. PubMed ID: 1818177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat.
    Theus SA; Andrews RP; Steele P; Walzer PD
    J Clin Invest; 1995 Jun; 95(6):2587-93. PubMed ID: 7769101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant major surface glycoprotein of Pneumocystis carinii elicits a specific immune response but is not protective in immunosuppressed rats.
    Lasbury ME; Angus CW; Klivington D; Durant PJ; Bartlett MS; Smith JW; Lee CH
    J Eukaryot Microbiol; 1999; 46(5):136S-137S. PubMed ID: 10519289
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthetic p55 tandem DNA vaccine against Pneumocystis carinii in rats.
    Fan H; Guo JY; Ma SL; Zhang N; An CL
    Microbiol Immunol; 2016 Jun; 60(6):397-406. PubMed ID: 27185490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response.
    Theus SA; Smulian AG; Steele P; Linke MJ; Walzer PD
    Vaccine; 1998 Jul; 16(11-12):1149-57. PubMed ID: 9682373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of mouse Pneumocystis carinii surface glycoprotein A.
    Haidaris CG; Medzihradsky OF; Gigliotti F; Simpson-Haidaris PJ
    DNA Res; 1998 Apr; 5(2):77-85. PubMed ID: 9679195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice.
    Harmsen AG; Chen W; Gigliotti F
    Infect Immun; 1995 Jul; 63(7):2391-5. PubMed ID: 7790048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody.
    Lund FE; Schuer K; Hollifield M; Randall TD; Garvy BA
    J Immunol; 2003 Aug; 171(3):1423-30. PubMed ID: 12874234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary studies on the development of a vaccine for Pneumocystis carinii. I. Immunological and biochemical characterization.
    Pifer LL; Pifer DD; Woods DR; Joyner RE; Edwards CC
    Vaccine; 1986 Dec; 4(4):257-65. PubMed ID: 3541429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.